Literature DB >> 8212992

Effect of triptorelin (Decapeptyl) combined with heparin on estradiol levels in MCF-7 mammary cancer cells after incubation with estrone sulfate.

J R Pasqualini1, J Blumberg-Tick, B L Nguyen.   

Abstract

The effects of triptorelin (Decapeptyl) and heparin, alone or in combination, on the intracellular concentration of estradiol (E2) after incubation of estrone sulfate (E1S) with the MCF-7 mammary cancer cells was investigated. Although heparin (10 mg/l culture medium) or Decapeptyl (5 x 10(-7) or 5 x 10(-5) mol/l) did not affect the levels of radioactive E2 after incubation with [3H]E1S, the combination of Decapeptyl and heparin significantly decreased the radioactive uptake and the intracellular concentrations of [3H]E2. In the absence of Decapeptyl and heparin incubations with E1S, the resulting E2 concentration (in nmol/kg DNA +/- SD) was 558 +/- 44; after heparin (10 mg/l) plus Decapeptyl (5 x 10(-7) or 5 x 10(-5) mol/l) the values were 389 +/- 55 and 165 +/- 18, respectively. It is concluded that Decapeptyl with heparin can decrease very significantly the conversion of E1S to E2 in MCF-7 cells, an observation that suggests new possibilities for the control of E2 in hormone-dependent breast cancer.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8212992     DOI: 10.1530/acta.0.1290260

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  2 in total

1.  Emodin-Loaded PLGA-TPGS Nanoparticles Combined with Heparin Sodium-Loaded PLGA-TPGS Nanoparticles to Enhance Chemotherapeutic Efficacy Against Liver Cancer.

Authors:  Hongyan Liu; Hong Xu; Chenghong Zhang; Meng Gao; Xiaoguang Gao; Chuchu Ma; Li Lv; Dongyan Gao; Sa Deng; Changyuan Wang; Yan Tian
Journal:  Pharm Res       Date:  2016-08-10       Impact factor: 4.200

Review 2.  Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer.

Authors:  Marta Venturelli; Giorgia Guaitoli; Claudia Omarini; Luca Moscetti
Journal:  Breast Cancer (Dove Med Press)       Date:  2018-03-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.